An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma

An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma

Archaeosomes constitute archaeal lipid vesicle vaccine adjuvants that evoke a strong CD8+ T cell response to antigenic cargo. Therapeutic treatment of murine B16-ovalbumin (B16-OVA) melanoma with archaeosome-OVA eliminates small subcutaneous solid tumors; however, they eventually resurge despite an...

Full description

Bibliographic Details
Main Authors: Felicity C. Stark, Risini D. Weeratna, Lise Deschatelets, Komal Gurnani, Renu Dudani, Michael J. McCluskie, Lakshmi Krishnan
Format: Article
Language:English
Published: MDPI AG 2017-10-01
Series:Vaccines
Subjects:
checkpoint inhibitor
PD-1
PD-L1
CTLA-4
tumor-infiltrating lymphocyte (TIL)
cancer vaccine
CD8+ T cell response
archaeosome
prime-boost
B16
liposome
tumor vaccine
effector T cell (TE)
effector memory T cell (TEM)
Online Access:https://www.mdpi.com/2076-393X/5/4/38

Internet

https://www.mdpi.com/2076-393X/5/4/38

Similar Items